Multiple sclerosis, disease modifying treatments and depression: a critical methodological review
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Background: Major depression affects one in two patients with multiple sclerosis (MS) during the course of their lifetime. This adds to the morbidity associated with the disorder and may contribute to an increased mortality rate because of suicide. Over the past few years, with the advent of disease modifying treatments for MS, a new concern with respect to mood has arisen, namely the possibility that some of these drugs may have depression as a clinically significant side effect. Objective: To ascertain whether disease modifying treatments in MS are associated with the development of depression or the worsening of a depressive illness. Methodology: A MEDLINE and PSYCHLIT search focusing on depression and disease modifying treatments going back to 1993 (the publication date of the results of the first randomised, placebo controlled trial). The methodology pertaining to the assessment of depression is critically reviewed. Furthermore, a critical summary is provided of treatment modalities for the depressed MS patient. Results: There are conflicting data that depression may occur with some disease modifying drugs, particularly interferon beta-1b. However, all studies reveal limitations with respect to the assessment of mood. Some reports, despite omitting details of how mentation was assessed, still comment on the presence or absence of depression. Others suffer from one or more of the following shortcomings: a failure to assess premorbid risk factors for mood disorder; a reliance on one question to assess depression; the utilisation of self report mood rating scales of questionable validity; neglecting to distinguish depression as a symptom from depression as a syndrome (i.e. major depression as defined by the DMS-1V). Conclusions: Given the many methodological pitfalls inherent in all studies to date, it is premature to conclude that disease modifying drugs are associated with depression. Evidence suggests that treatment of depression, irrespective of a putative association with a disease modifying agent, is frequently effective. This applies to pharmacotherapy or psychotherapy, although the former may be preferred should depression arise during a course of treatment with a disease modifying agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kappos, L. (1998) · The Lancet · doi:10.1016/s0140-6736(98)10039-9 · Cited by 936
Treatment of depression in multiple sclerosis: Review and meta-analysis.
Mohr, D. C., & Goodkin, D. E. (1999) · Clinical Psychology: Science and Practice · doi:10.1093/clipsy.6.1.1 · Cited by 155
Nyenhuis, D. L., & Luchetta, T. (1998) · Journal of Personality Assessment · doi:10.1207/s15327752jpa7002_14 · Cited by 155
Mohr, D. C., Goodkin, D. E., Likosk, W., Gatto, N., Neilley, L. K., Griffin, C., & Stiebling, B. (1996) · Multiple Sclerosis Journal · doi:10.1177/135245859600200502 · Cited by 131
Cited by
Depression in multiple sclerosis: a review
Siegert, R. J. (2005) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2004.054635 · Cited by 718
“10 The initial concern apparently sprang from reports of a suicide and four attempted suicides that occurred among the treated group in the first clinical trial.”
BackgroundQuality of life in multiple sclerosis: the impact of depression, fatigue and disability
Amato, M. P., Ponziani, G., Rossi, F., Liedl, C. L., Stefanile, C., & Rossi, L. (2001) · Multiple Sclerosis Journal · doi:10.1177/135245850100700511 · Cited by 506
The Goldman Consensus statement on depression in multiple sclerosis
Goldman Consensus Group (2005) · Multiple Sclerosis Journal · doi:10.1191/1352458505ms1162oa · Cited by 329
Structural brain abnormalities in multiple sclerosis patients with major depression
Feinstein, A., Roy, P., Lobaugh, N., Feinstein, K., O’Connor, P., & Black, S. (2004) · Neurology · doi:10.1212/01.wnl.0000110316.12086.0c · Cited by 294
Self-citationAutoimmune diseases, bipolar disorder, and non-affective psychosis
Eaton, W. W., Pedersen, M. G., Nielsen, P. R., & Mortensen, P. B. (2010) · Bipolar Disorders · doi:10.1111/j.1399-5618.2010.00853.x · Cited by 262
“As with bipolar disorder, the relationship is clouded by the possibility that treatment for MS is connected to affective state (19).”
Metadata
- Authors
- Feinstein, A.
- Venue
- Multiple Sclerosis Journal
- Publisher
- SAGE Publications
- Published
- 2000-10
- Volume
- 6
- Issue
- 5
- Pages
- 343-348
- ISSN
- 1352-4585 (ISSN-L)
- 1477-0970
- OpenAlex
- W1985235854
- Cited by
- 69
- References
- 4
- FWCI
- 1.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Multiple sclerosis, disease modifying treatments and depression: a critical methodological review. https://app.cochat.ai/papers/10.1177/135245850000600509
- The paper
- Feinstein, A. (2000). Multiple sclerosis, disease modifying treatments and depression: a critical methodological review. Multiple Sclerosis Journal. https://doi.org/10.1177/135245850000600509
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.